Evaluation of the Effect of Regular Administration of Coagulant Factors on the Joint Pain Level and Dimensions of the Quality of Life of the Patients  Suffering from Some Bleeding Disorders (BDs)

Marzieh Poursamimi; Soleyman Saravani; Fatemeh Akbari Motlaq; Yahya Ehsanollahi; Javad Poursamimi

doi:10.18502/jzms.v6i3.14797

Marzieh Poursamimi MSc in Clinical Psychology, Department of Clinical Psychology, Faculty of Humanities, Islamic Azad University, Sirjan, Iran
Soleyman Saravani PhD in Healthcare Services Management, Department of Community Medicine, School of Medicine, Zabol University of Medical Sciences, Zabol, Iran
Fatemeh Akbari Motlaq Assistant Student in Gynecology, School of Medicine, Zabol University of Medical Sciences, Zabol, Iran
Yahya Ehsanollahi Assistant Professor, Department of Surgery, School of Medicine, Amir al momenin Hospital, Zabol University of Medical Sciences, Zabol, Iran
Javad Poursamimi Assistant Professor, Department of Medical Immunology, School of Medicine, Zabol University of Medical Sciences, Zabol, Iran

DOI: https://doi.org/10.18502/jzms.v6i3.14797

Keywords: Hemophilia; Quality of life, Coagulation; Coagulant factors; Joint; Pain

Abstract

Background: Blood coagulation is a process that prevents blood loss. Lack of coagulation factors (inherited or acquired) disrupts this path. The prevalence of coagulant deficiency including VIII and XIII factors in Sistan and Baluchistan province is higher than in other parts of Iran. This study aimed to investigate the condition of patients suffering from some bleeding disorders (BDs) in terms of regular coagulant takes and their effects on quality of life.

Methods: Our cross-sectional study was descriptive-analytical. Thirty-five BD patients suffering the blood coagulant deficiency enrolled, and were sorted into 5 groups.

Results: The mean (±SD) age in the hemophilia A and B groups were
(16.25 ± 8.15), and (8.14 ± 3.9), and other coagulation factor deficiencies including VWF, XIII, and IX were (15.1 ± 7.8), (15.5 ± 2.4), and IX (19.0 ± 11.5) respectively. The quality of life in group A (81.3 ± 14.9) compared to groups B (50 ± 0.25) and IX (47.5 ± 24.1) had a significant difference (p value < 0.05). In addition, there was a significant difference in group XIII (79.2 ± 29.2) compared to groups B (50 ± 0.25) and IX (47.5 ± 24.1) (p value < 0.05). Generally, the quality of life was higher in women (10 people) (72.5 ± 26.2) than in men
(26 people) (61.1 ± 24.5). Furthermore, the Visual analog scale for pain in group A (1.3 ± 0.4) had a significant difference compared to group B (3.5 ± 0.43), IX (7.8 ± 0.9), XIII (0.4 ± 4.3) and VWF (3.2 ± 0.38) (p value < 0.05).

Conclusion: In sum, patients with hemophilia A and coagulation factor XIII deficiency had low levels of joint pain and a high level of quality of life dimensions.